Zacks8d agobearish
Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock FallsOCGN posts a wider Q2 loss as R&D spending climbs, while advancing late-stage gene therapy programs and extending its cash runway into 2028.
Actualités
Uniquement les titres à fort signal - événements macro, résultats, M&A, régulation. Listicles et clickbait d'analystes filtrés par défaut. Rafraîchi toutes les heures.
40last 24h
1802last 7d
299● bullish (7d)
170● bearish (7d)
205publishers
Zacks101d agobearish
OCGN Falls on Wider Q1 Loss Despite Strong Pipeline Progress OutlookOcugen swings to a wider Q1 loss as costs climb, but pipeline milestones and gene therapy data keep its long-term plans on track.